Pharmaceutical interventions play a pivotal role in managing neuropsychiatric disorders. Despite ongoing challenges in understanding the underlying pathological mechanisms of many of these conditions, research into the pharmacodynamics of therapeutic agents has not only shed light on these mechanisms but also elucidated brain function mechanisms at the molecular level. However, the variability in drug response among individuals underscores the necessity for thorough pharmacological investigations to ensure safe and effective usage, considering the potential side effects associated with these medications.Furthermore,the absence of effective pharmacotherapies for certain neuropsychiatric disorders, or the limited efficacy of existing treatments, underscores the pressing need for the development of novel therapeutic agents.To address these challenges, the Department of Neuropsychopharmacology has established two key Sections: the Section of Molecular Pharmacology and the Section of Drug Development. These facilities are dedicated to:
1. Investigating the mechanisms underlying the therapeutic actions of drugs used in treating neuropsychiatric disorders.
2. Promoting the judicious and informed use of pharmacotherapies for neuropsychiatric conditions.
3. Advancing research efforts towards the development of innovative pharmacological treatments for neuropsychiatric disorders.
Moreover, our department is committed to enhancing Japan's global leadership in the responsible utilization and development of novel pharmacotherapies for neuropsychiatric disorders. By fostering a robust research infrastructure, we aim to catalyze collaborative endeavors across industry, government, and academia nationwide, thereby driving progress in this critical field.